Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5944
    +0.0007 (+0.12%)
     
  • NZD/EUR

    0.5549
    +0.0003 (+0.06%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.70
    -0.11 (-0.13%)
     
  • GOLD

    2,332.00
    -6.40 (-0.27%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,265.46
    +64.19 (+0.37%)
     
  • NIKKEI 225

    37,803.46
    -656.62 (-1.71%)
     
  • NZD/JPY

    92.3420
    +0.2270 (+0.25%)
     

Is Ocugen Finally on the Way to Vaccine Revenue?

Is Ocugen Finally on the Way to Vaccine Revenue?

Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.